ALLMedicine™ Blepharitis Center

Jan 23rd, 2023 - Specific Organisms and Therapeutic Regimens Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50. [1] Clinically, there is irritation of...

Jan 23rd, 2023 - Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50.[1] Clinically, there is irritation of the eyelid margins as well as flaking/crusti...

Jan 23rd, 2023 - Specific Organisms and Therapeutic Regimens Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50. [1] Clinically, there is irritation of...

Jan 19th, 2023 - Dyskeratosis congenita and related telomere biology disorders (DC/TBD) are caused by impaired telomere maintenance resulting in short or very short telomeres. The phenotypic spectrum of telomere biology disorders is broad and includes individuals ...

Jan 19th, 2023 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbat...

Oct 28th, 2018 - Blepharitis Preferred Practice Pattern®.|2018|Amescua G,Akpek EK,Farid M,Garcia-Ferrer FJ,Lin A,|organization & administration,therapeutic use,diagnosis,drug therapy,diagnosis,therapeutic use,pathology,organization & administration,standards,stand...

Jan 19th, 2023 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbat...

Dec 14th, 2022 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of ble...

Dec 2nd, 2022 - This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the...

Nov 29th, 2022 - The main study is designed to demonstrate the superiority of 0.25%TP-03 to vehicle for the treatment of Demodex blepharitis in China. The vehicle of TP-03 was selected as the control since there are no approved pharmaceutical treatments for Demode...

Nov 8th, 2022 - This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

Nov 21st, 2022 - To the Editor: Atopic diseases, specifically atopic dermatitis (AD) and alopecia areata (AA), are at the forefront of a new era in dermatology involving molecular-directed therapy. Dupilumab is one specific example, having received US Food and Dru.

Nov 18th, 2022 - This patient's symptoms are consistent with a diagnosis of blepharitis. Blepharitis is an inflammatory disorder of the eyelids that is frequently associated with bacterial colonization of the eyelid.

Oct 17th, 2022 - Although ocular monkeypox is rare, it can be a condition that threatens a person's sight, a Centers for Disease Control and Prevention (CDC) report says. The report details five people with monkeypox who developed eye complications from July throu...

Aug 27th, 2022 - Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects (TEAEs) that may arise with belantamab mafodotin-blmf (Blenrep) in patients with relapsed/refractory multiple myeloma, according to a pos...

Dec 25th, 2021 - Key clinical point: Ocular surface diseases (OSD), particularly conjunctivitis, are prevalent among patients with atopic dermatitis (AD), with the prevalence increasing with AD severity and childhood onset of AD. Major finding: Of all OSDs, lifeti.